

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 15, 2019

Date of Report

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation)

001-37939

(Commission File Number)

45-4497941

(IRS Employer Identification No.)

5 West Forsyth Street
Suite 200

Jacksonville, FL

(Address of principal executive offices)

32202

(Zip Code)

(904) 516-5436

Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On January 15, 2019, Marker Therapeutics, Inc. (“Marker” or the “Company”) issued a press release announcing that the Center for Cell and Gene Therapy at Baylor College of Medicine was to present data from four abstracts at the meetings of the American Society for Blood and Marrow Transplantation (“ASBMT”). The studies summarize data achieved using multi-tumor antigen specific T cells that were developed at Baylor College of Medicine and exclusively licensed to the Company. The meetings of ASBMT are from February 20-24, 2019 and will take place in Houston, Texas.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
-------------	-------------

99.1	Press release issued on January 15, 2019.
----------------------	---

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 15th day of January, 2019.

MARKER THERAPEUTICS, INC.
(Registrant)

BY: /s/ Michael Loiacono

Michael Loiacono
Chief Accounting Officer



**The Center for Cell and Gene Therapy at Baylor College of Medicine to
Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019**

Houston, TX – January 15, 2019 – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the *Center for International Blood and Marrow Transplant Research* (ASBMT and CIBMTR). The studies summarize data achieved using multi-tumor antigen specific T cells that were developed at Baylor College of Medicine in the laboratories of Dr. Swati Naik, Dr. Ann Leen, and Dr. Premal Lulla, and exclusively licensed to Marker.

The TCT meetings of ASBMT and CIBMTR 2019 will take place in Houston, TX from February 20-24.

Oral Presentation Details

Presentation Title: “Targeting Lymphomas Using Non-Engineered, Multi-Antigen-Specific T Cells” (Abstract #24)

Session Title: Session C - Lymphoma and Myeloma

Session Date/Time: Wednesday, February 20, 2019, 5:00 p.m. CST

Presentation Title: “Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse” (Abstract #11)

Session Title: Session A - Acute and Chronic Leukemia

Session Date/Time: Wednesday, February 20, 2019, 5:45 p.m. CST

Presentation Title: “Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor-Associated Antigens” (Abstract #78)

Session Title: Session K - Immune and Gene Therapy

Session Date/Time: Saturday, February 23, 2019, 5:00 p.m. CST

Poster Presentation Details

Presentation Title: “Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma” (Abstract #621)

Presentation Date/Time: Saturday, February 23, 6:45 p.m. CST

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.

For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com

To receive future press releases via email, please visit: <https://markertherapeutics.com/email-alerts/>

Follow us on Twitter [@MRKRTerapeutic](https://twitter.com/MRKRTerapeutic), or follow us on [Facebook](https://www.facebook.com/MarkerTherapeutics).

Forward-Looking Statement Disclaimer

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™ program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success of our clinical trials, as well as multi-tumor antigen specific T cell clinical trials conducted by Baylor College of Medicine. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts

Marker Therapeutics, Inc.

Aaron Santos

(904) 862-6490

investor.relations@markertherapeutics.com

Solebury Trout

Brad Miles

(646) 513-3125

bmiles@soleburytrout.com

- or -

Amy Bonanno

(914) 450-0349

abonanno@soleburytrout.com